PDF(Pubmed)
Abstract：
UNASSIGNED: Sarcopenia is closely associated with postoperative prognosis in patients undergoing cardiovascular surgery. Growth differentiation factor (GDF)-15 is involved in the pathogenesis of cardiovascular disease. We examined the relationship between the serum GDF-15 concentration and muscle function in patients receiving aortic valve replacement and healthy elderly subjects.
UNASSIGNED: Forty-three female patients undergoing aortic valve surgery (79.9 ± 6.4 years; transcatheter aortic valve replacement [TAVR] n = 19, conventional surgical aortic valve replacement [SAVR] n = 24) and 64 healthy elderly female subjects (75.9 ± 6.1 years) were included. Walking speed, grip strength, and skeletal muscle mass index (SMI) by a multifrequency bioelectrical impedance analyzer were measured to determine the presence of sarcopenia. Preoperative serum GDF-15 concentration was measured by enzyme-linked immunosorbent assay.
UNASSIGNED: The GDF-15 level was higher in patients receiving aortic valve replacement than in healthy elderly subjects (aortic valve replacement: 1624 ± 1186 pg/mL vs. healthy: 955 ± 368 pg/mL, p < 0.001). Multivariate linear regression analysis showed that the serum GDF-15 level determined grip strength independently of the high-sensitivity C-reactive protein level and eGFR, even after adjusting for age (β = -0.318, p = 0.025). Sarcopenia was found in 12.5% of healthy elderly subjects, 83.3% of patients with TAVR, and 64.3% of patients with SAVR. The GDF-15 concentration that defined sarcopenia was 1109 pg/mL in subjects including patients receiving aortic valve replacement.
UNASSIGNED: The preoperative serum GDF-15 concentration, which was higher in female patients receiving aortic valve replacement than in healthy elderly subjects, may be a serum marker of sarcopenia.
UNASSIGNED: Forty-three female patients undergoing aortic valve surgery (79.9 ± 6.4 years; transcatheter aortic valve replacement [TAVR] n = 19, conventional surgical aortic valve replacement [SAVR] n = 24) and 64 healthy elderly female subjects (75.9 ± 6.1 years) were included. Walking speed, grip strength, and skeletal muscle mass index (SMI) by a multifrequency bioelectrical impedance analyzer were measured to determine the presence of sarcopenia. Preoperative serum GDF-15 concentration was measured by enzyme-linked immunosorbent assay.
UNASSIGNED: The GDF-15 level was higher in patients receiving aortic valve replacement than in healthy elderly subjects (aortic valve replacement: 1624 ± 1186 pg/mL vs. healthy: 955 ± 368 pg/mL, p < 0.001). Multivariate linear regression analysis showed that the serum GDF-15 level determined grip strength independently of the high-sensitivity C-reactive protein level and eGFR, even after adjusting for age (β = -0.318, p = 0.025). Sarcopenia was found in 12.5% of healthy elderly subjects, 83.3% of patients with TAVR, and 64.3% of patients with SAVR. The GDF-15 concentration that defined sarcopenia was 1109 pg/mL in subjects including patients receiving aortic valve replacement.
UNASSIGNED: The preoperative serum GDF-15 concentration, which was higher in female patients receiving aortic valve replacement than in healthy elderly subjects, may be a serum marker of sarcopenia.
摘要：
未经证实：肌少症与心血管手术患者术后预后密切相关。生长分化因子(GDF)-15参与心血管疾病的发病。我们检查了接受主动脉瓣置换术的患者和健康老年受试者的血清GDF-15浓度与肌肉功能之间的关系。
UNASSIGNED：43例接受主动脉瓣手术的女性患者（79.9±6.4岁；经导管主动脉瓣置换术[TAVR]n=19，常规手术主动脉瓣置换术[SAVR]n=24）和64例健康老年女性受试者（75.9±6.1岁）。步行速度，握力,通过多频生物电阻抗分析仪测量和骨骼肌质量指数（SMI）以确定是否存在肌肉减少症。术前血清GDF-15浓度测定采用酶联免疫吸附法。
UNASSIGNED：接受主动脉瓣置换术的患者的GDF-15水平高于健康的老年受试者（主动脉瓣置换术：1624±1186pg/mL与健康:955±368pg/mL,p<0.001)。多元线性回归分析显示,血清GDF-15水平独立于超敏C反应蛋白水平和eGFR,即使调整了年龄(β=-0.318，p=0.025)。12.5%的健康老年受试者发现肌肉减少症，83.3%的TAVR患者,64.3%的SAVR患者。在受试者(包括接受主动脉瓣置换的患者)中,定义少肌症的GDF-15浓度为1109pg/mL。
未经批准：术前血清GDF-15浓度，这在接受主动脉瓣置换术的女性患者中高于健康的老年受试者，可能是肌肉减少症的血清标志物。
UNASSIGNED：43例接受主动脉瓣手术的女性患者（79.9±6.4岁；经导管主动脉瓣置换术[TAVR]n=19，常规手术主动脉瓣置换术[SAVR]n=24）和64例健康老年女性受试者（75.9±6.1岁）。步行速度，握力,通过多频生物电阻抗分析仪测量和骨骼肌质量指数（SMI）以确定是否存在肌肉减少症。术前血清GDF-15浓度测定采用酶联免疫吸附法。
UNASSIGNED：接受主动脉瓣置换术的患者的GDF-15水平高于健康的老年受试者（主动脉瓣置换术：1624±1186pg/mL与健康:955±368pg/mL,p<0.001)。多元线性回归分析显示,血清GDF-15水平独立于超敏C反应蛋白水平和eGFR,即使调整了年龄(β=-0.318，p=0.025)。12.5%的健康老年受试者发现肌肉减少症，83.3%的TAVR患者,64.3%的SAVR患者。在受试者(包括接受主动脉瓣置换的患者)中,定义少肌症的GDF-15浓度为1109pg/mL。
未经批准：术前血清GDF-15浓度，这在接受主动脉瓣置换术的女性患者中高于健康的老年受试者，可能是肌肉减少症的血清标志物。
